Groundbreaking Research Proves Efficacy of PlusCBD™ Oil in Sleep, Wellness and Weight-Loss Applications
First-Ever Double-Blind, Randomized Study Titled, “Effects of a CBD-containing Supercritical Fluid Extract of Hemp on Markers of Optimal Wellness, Stress Resilience, and.
CV Sciences, Inc. to Present at the Oppenheimer 19th Annual Consumer Conference
LAS VEGAS, June 13, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”) a preeminent supplier and manufacturer of hemp CBD products.
CBD leader CV Sciences jumps 10% on Kroger deal to sell CBD oil in 17 US states
Shares of CBD company CV Sciences jumped 10% on a deal with retailer Kroger to sell its oils in nearly 1,000 stores.
CV Sciences, Inc. Announces New Distribution With Kroger and Expands Its Offering of Topical Products
PlusCBD™ Oil Roll-On Launch at 945 Kroger Stores in 17 U.S. States LAS VEGAS, June 12, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or.
CV Sciences Comments on FDA CBD Hearing
Top hemp CBD Company urges FDA to swiftly develop regulations to separate an agricultural commodity from a controlled substance and ensure consumer safety LAS VEGAS, June 06,.
Cannabis Legalization Has Taken a Couple of Big Steps Forward
Illinois became the first state to approve approved recreational marijuana use for adults by legislature, as opposed to a voter referendum.
CV Sciences, Inc. Applauds California Assembly Support of Hemp-derived CBD products through Unanimous Passi
CV Sciences, Inc. (CVSI) (the “Company”, “”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products through its industry-dominating brand, PlusCBD Oil™, announces...
CV Sciences’ PlusCBD Oil™ Used in First Study Examining Clinical Benefit of CBD for Patients with PTSD
CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announced that its industry-dominating...
Edited Transcript of CVSI earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 CV Sciences Inc Earnings Call
CV Sciences, Inc. Reports First Quarter 2019 Financial Results
Record quarterly revenue Increased retail distribution by over 1,000 stores LAS VEGAS, May 08, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) ("CV Sciences" or the “Company”).
CV Sciences, Inc., a life sciences organization, is focused on promoting healthy living through their pharmaceutical drug development efforts and portfolio of finished product brands. CV Sciences’ Pharmaceutical Division is developing synthetically‐formulated cannabidiol‐based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences’ Consumer Products Division delivers botanical‐based cannabidiol products